Principal Financial Group Inc. Acquires 86,764 Shares of SOPHiA GENETICS SA (NASDAQ:SOPH)

Principal Financial Group Inc. boosted its holdings in SOPHiA GENETICS SA (NASDAQ:SOPH) by 6.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,455,142 shares of the company’s stock after acquiring an additional 86,764 shares during the period. Principal Financial Group Inc. owned 2.23% of SOPHiA GENETICS worth $5,290,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the business. Banque Cantonale Vaudoise increased its holdings in shares of SOPHiA GENETICS by 300.0% in the second quarter. Banque Cantonale Vaudoise now owns 12,000 shares of the company’s stock valued at $55,000 after purchasing an additional 9,000 shares during the last quarter. Green Alpha Advisors LLC acquired a new position in SOPHiA GENETICS in the 3rd quarter valued at about $79,000. Finally, Federated Hermes Inc. raised its holdings in SOPHiA GENETICS by 57.5% in the 2nd quarter. Federated Hermes Inc. now owns 63,000 shares of the company’s stock valued at $289,000 after acquiring an additional 23,000 shares during the period. Institutional investors own 31.59% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Royal Bank of Canada reduced their price objective on SOPHiA GENETICS from $8.00 to $7.00 and set an “outperform” rating for the company in a report on Wednesday, August 7th. Morgan Stanley downgraded SOPHiA GENETICS from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $10.00 to $5.00 in a research note on Wednesday, August 7th.

SOPHiA GENETICS Stock Performance

Shares of NASDAQ:SOPH opened at $3.17 on Thursday. SOPHiA GENETICS SA has a 12-month low of $2.70 and a 12-month high of $7.37. The company’s 50 day moving average price is $3.61 and its two-hundred day moving average price is $4.13. The firm has a market cap of $207.24 million, a PE ratio of -2.91 and a beta of 1.03. The company has a quick ratio of 3.59, a current ratio of 3.80 and a debt-to-equity ratio of 0.12.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). The company had revenue of $15.85 million for the quarter, compared to the consensus estimate of $15.90 million. SOPHiA GENETICS had a negative return on equity of 55.06% and a negative net margin of 110.71%. During the same quarter last year, the business earned ($0.21) EPS. Equities research analysts predict that SOPHiA GENETICS SA will post -0.95 earnings per share for the current year.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.